Antiarrhythmic drug development: Historical review and future perspective

Drug Development Research

Volumn 55, Issue 1, 2002, Pages 3-16

  Pugsley, Michael K ^a  

^a XOMA Corporation   (United States)

Author keywords

Antiarrhythmics; Ischemia; Proarrhythmia; Sicilian Gambit; Vaughan Williams

Indexed keywords

1 NAPHTHALENEACETIC ACID 2 MORPHOLINOCYCLOHEXYL ESTER; AMIODARONE; ANTIARRHYTHMIC AGENT; ATENOLOL; AZIMILIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DILTIAZEM; DISOPYRAMIDE; DOFETILIDE; DRONEDARONE; ENCAINIDE; ESMOLOL; FLECAINIDE; IBUTILIDE; LIDOCAINE; METOPROLOL; MEXILETINE; MORACIZINE; PHENYTOIN; POTASSIUM CHANNEL; POTASSIUM CHANNEL BLOCKING AGENT; PROCAINAMIDE; PRONETALOL; PROPRANOLOL; QUINIDINE; SODIUM CHANNEL; SODIUM CHANNEL BLOCKING AGENT; SOTALOL; TRANSCAINIDE; UNINDEXED DRUG; VERAPAMIL;

ARRHYTHMOGENESIS; CLINICAL TRIAL; DISEASE MODEL; DRUG DEVELOPMENT; DRUG MECHANISM; DRUG SELECTIVITY; DRUG TARGETING; HEART ELECTROPHYSIOLOGY; HEART MUSCLE ISCHEMIA; HEART PROARRHYTHMIA; HEART SUPRAVENTRICULAR ARRHYTHMIA; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE FIBRILLATION; HUMAN; MORTALITY; NONHUMAN; POTASSIUM CURRENT; REVIEW; SIDE EFFECT; SODIUM CURRENT; SURVIVAL RATE;

EID: 0036215014     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/ddr.10036     Document Type: Review

References (121)

1. Azimilide dihydrochloride: A new class III anti-arrhythmic agent
2. Cellular and in vivo electrophysiological effects of dronedarone in normal and postmyocardial infarcted rats
3. Better antiarrhythmics? Development ofantiarrhythmic drugs selective for ischaemia-dependent arrhythmias
4. Lack of selectivity for ventricular and ischaemic tissue limits the antiarrrhythmic actions of lidocaine, quinidine and flecainide against ischaemia-induced arrhythmias
5. RSD1019 suppresses ischaemia-induced monophasic action potential shortening and arrhythmias in anaesthetized rabbits
6. Sodium channel block by a potent new antiarrhythmic agent, transcainide, in guinea pig ventricular myocytes
7. The effect of modification of sympathetic activity on responses to ligation of a coronary artery in the conscious rat
8. Arrhythimias associated with myocardial ischaemia and infarction
9. Peripheral adrenergic mechanisms
10. Post-myocardial infarction mortality in patients with ventricular premature depolarizations
11. Importance of physico-chemical properties in determining the kinetics of the effects of class I antiarrhythmic drugs on maximum rate of depolarization in guinea-pig ventricle
12. Kinetics of onset and rate-dependent effects of class I antiarrhythmic drugs are important in determining their effects on refractoriness in guinea pig ventricle, and provide a theoretical basis for their subclassification
13. Subclassification of class I antiarrhythmic drugs
14. Selectivity of antiarrhythmic drugs and ionic channels: A historical overview
15. Mechanisms and control of repolarization
16. Preliminary report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction
17. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction
18. max in guinea pig ventricular myocardium
19. Arrhythmia models in the rat
20. Electrophysiological evidence that local anesthetics and antiarrhythmic drugs bind to a specific receptor site in cardiac sodium channels: Displacement of bupivacaine by lidocaine
21. Evidence for two components of sodium channel block by lidocaine in isolated cardiac myocytes
22. The Sicilian Gambit and antiarrhythmic drug development
23. + channel blockers and activators in cardiac arrhythmias
24. Channel specificity in antiarrhythmic drug action. Mechanism of potassium channel block and its role in suppressing and aggravating cardiac arrhythmias
25. Molecular mechanisms of potassium channel block by antiarrhythmic drugs
26. Characterization of a new oral antiarrhythmic drug, flecainide (R818)
27. Endogenous chemical mediators of ventricular arrhythmias in ischaemic heart disease
28. Use-dependent effects of lidocaine on conduction in canine myocardium: Application of the modulated receptor hypothesis in vivo
29. Experimental models of reentry, antiarrhythmic, and proarrhythmic actions of drugs. Complexities galore!
30. Models of drug interaction with the sodium channel
31. Effects of diphenylhydantoin sodium and phenobarbital sodium upon ectopic ventricular tachycardia in acute myocardial infarction
32. Antiarrhythmic drug classification: New science and practical application
33. Is there a rational basis for the modified classification of antiarrhythmic drugs?
34. The Sicilian Gambit: Reasons for maintaining the present antiarrhythmic drug classification
35. Encainide: A new and potent antiarrhythmic agent
36. Myocardial ischaemia and metabolic changes associated with the genesis of ventricular arrhythmias
37. Local anaesthetics: Hydrophilic and hydrophobic pathways for the drug-receptor reaction
38. Meta-analytic evidence against prophylactic use of lidocaine in acute myocardial infarction
39. Quantitative description of membrane current and its application to conduction and excitation in nerve
40. Antiarrhythmic drugs
41. Antiarrhythmic agents: Modulated receptor applications
42. Molecular interactions of antiarrhythmic agents with their receptor sites
43. Development of class III antiarrhythmic agents
44. a properties
45. Models of antiarrhythmic drug action
46. Time and voltage dependent interactions of antiarrhythmic drugs with cardiac sodium channels
47. Antiarrhythmic agents: The modulated receptor mechanism of action of sodium and calcium channel-blocking drugs
48. Quinidine blocks cardiac sodium channels during opening and slow inactivation in guinea pig papillary muscle
49. Class III antiarrhythmic agents have a lot of potential but a long way to go
50. Antiarrhythmic drug action: Selective depression of hypoxic cardiac cells
51. New anti-arrhythmia agents
52. The efficacy of antiarrhythmic agents during acute myocardial ischemia and the role of heart rate
53. Comparison of K channels in mammalian atrial and ventricular myocytes
54. International mexiletine and placebo antiarrhythmic coronary trial: I. Report on arrhythmia and other findings
55. The long QT syndromes: A critical review, new clinical observations and a unifying hypothesis
56. To prolong refractoriness or to delay conduction (or both)?
57. Electrophysiological actions of diphenylhydantoin on rabbit atria
58. The differential effects of quinidine and pyrilamine on the myocardial action potential at various rates of stimulation
59. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT
60. Treatment and prevention of sudden cardiac death - What have we learnt from randomised clinical trials?
61. Pharmacology and clinical assessment of cariporide for the treatment of coronary artery diseases
62. New class III antiarrhythmic drugs
63. Antiarrhythmic drug classifications and the clinician: A gambit in the land of chaos
64. Can antiarrhythmic agents be selected based on mechanism of action?
65. From first class to third class: Recent upheaval in antiarrhythmic therapy - Lessons from clinical trials
66. Ibutilide, a new compound with potent class III antiar-rhythmic activity, activates a slow inward Na+ current in guinea pig ventricular cells
67. The physiological disposition and cardiac effects of procainamide
68. Sotalol, hypokalaemia, syncope, and torsade de pointes
69. Quinidine-related mortality in the short-to medium-term treatment of ventricular arrhythmias: A meta analysis
70. Future evaluation of antiarrhythmic therapy
71. The site of action and active from of local anesthetics. I. Theory and pH experiments with tertiary compounds
72. Recent advances in understanding the pharmacology of amiodarone
73. Antiarrhythmic drug classifications. A critical appraisal of their history, present status, and clinical relevance
74. Evolution, mechanisms, and classification of antiarrhythmic drugs: Focus on Class III actions
75. Mortality reduction by antiadrenergie modulation of arrhythmogenic substrate: Significance of combining beta blockers and amiodarone
76. Arrhythmogenic effects of antiarrhythmic drugs
77. Proarrhythmia, a serious complication of antiarrhythmic drugs
78. Risks and benefits of antiarrhythmic therapy
79. Consequences of the Sicilian Gambit
80. The Sicilian Gambit: A response to Drs Colatsky and Harrison
81. Pharmacologic and behavioral effects on arrhythmias that immediately follow abrupt coronary occlusion: A canine model of sudden coronary death
82. Dofetilide (Tikosyn): A new drug to control atrial fibrillation
83. Amiodarone: Historical development and pharmacological profile
84. The classification of antiarrhythmic mechanisms of drug action: Experimental and clinical considerations
85. Comparative mechanisms of antiarrhythmic drugs
86. The effect of amiodarone, a new anti-anginal drug on cardiac muscle
87. A third class of antiarrhythmic action. Effects on atrial and ventricular intracellular potentials, and other pharmacological actions on cardiac muscle, of MJ 1999 and AH 3474
88. Effect of altering potassium concentration of the action of lidocaine and diphenylhydantoin on rabbit atrial and ventricular muscle
89. A fourth class of anti-dysrhythmic action? EfFect of verapamil on ouabain toxicity, on atrial and ventricular intracellular potentials, and on other features of cardiac function
90. The relevance of sympathetic activity in the pharmacological treatment of chronic stable angina
91. Current antiarrhythmic drugs: An overview of mechanisms of action and potential clinical utility
92. What niche will newer class iii antiarrhythmic drugs occupy?
93. Effects of quinidine on the sodium current of guinea pig ventricular myocytes. Evidence for a drug-associated rested state with altered kinetics
94. Ventricular fibrillation precipitated by cardiac catheterization
95. Theoretical characterization of ion channel blockade. Competitive binding to periodically accessible receptors
96. Phasic ion channel blockade. A kinetic model and parameter estimation procedure
97. Mechanisms of use-dependent block of sodium channels in excitable membranes by local anesthetics
98. Proarrhythmic response to sodium channel blockade: Theoretical model and numerical experiments
99. The inhibition of sodium currents in myelinated nerve by quaternary derivatives of lidocaine
100. Effects of tertiary local anesthetics and their quaternary derivatives on sodium channels of nerve membranes
101. Experimental models for the study of antiarrhythmic agents
102. Barium-induced nondriven action potentials as a model of triggered potentials from early after depolarizations: Significance of slow channel activity and differing effects of quinidine and amiodarone
103. The Sicilian Gambit. A new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms
104. Classification of anti-arrhythmic drugs
105. Adaptation to prolonged interruption of sympathetic drive, and protection against sudden death
106. A classification of antiarrhythmic actions reassessed after a decade of new drugs
107. Subgroups of class 1 antiarrhythmic drugs
108. Delayed ventricular repolarization as an antiarrhythmic principle
109. Relevance of cellular to clinical electrophysiology in interpreting antiarrhythmic drug action
110. Significance of classifying antiarrhythmic actions since the cardiac arrhythmia suppression trial
111. Antiarrhythmic therapy: A pathophysiologic approach
112. Aggravation and provocation of ventricular arrhythmias by antiarrhythmic drugs
113. Calcium channel blockers as antiarrhythmics
114. Animal models of human disease: Myocardial ischaemia and infarction
115. Effects of calcium ions and local anesthetics on electrical properties of Purkinje fibers
116. Methods in the detection and assessment of antiarrhythmic activity
117. Targeting ischaemia - Cell swelling and drug efficacy
118. RSD1000: A novel antiarrhythmic agent with increased potency under acidic and high-potassium conditions
119. Beta blockade during and after myocardial infarction: An overview of the randomized trials
120. The long QT interval syndrome. A Rosetta Stone for sympathetic related ventricular tachyarrhythmias